Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

Greenwich LifeSciences to Resume Stock Repurchase Program


Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, announced today it would resume its existing Stock Repurchase Program.

Under the repurchase program previously authorized by the board of directors, Greenwich LifeSciences may repurchase its outstanding shares of common stock from time to time in open market or privately-negotiated transactions, including accelerated share repurchase transactions, block trades, or pursuant to 10b5-1 trading plans. Any repurchases will be at management's discretion and will be subject to market conditions, the price of the Company's shares and other factors. The stock repurchase program may be modified, suspended or terminated by the Board of Directors at any time.

The Company has approximately $4.5 million available under the current program. As of its most recently reported quarter-end March 31, 2022, the Company had 12,951,453 shares of common stock outstanding.

About Greenwich LifeSciences, Inc.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75% of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. In a completed randomized, single-blinded, placebo-controlled, multi-center Phase IIb clinical trial led by MD Anderson Cancer Center, no recurrences were observed in patients treated with GLSI-100 in the HER2/neu 3+ adjuvant setting after median 5 years of follow-up, if the patients were treated, followed, and remained disease free over the first 6 months, which is the time required to reach peak immunity and thus maximum efficacy and protection (p = 0.0338). For the 146 patients who have been treated with GLSI-100 to date over 4 clinical trials, treatment was well tolerated and no serious adverse events were observed related to the immunotherapy. Greenwich LifeSciences is planning to commence a Phase III clinical trial using a similar treatment regime as the Phase IIb clinical trial. For more information on Greenwich LifeSciences, please visit the Company's website at www.greenwichlifesciences.com and follow the Company's Twitter at https://twitter.com/GreenwichLS.

Forward-Looking Statement Disclaimer

Statements in this press release contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Greenwich LifeSciences Inc.'s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including statements regarding the intended use of net proceeds from the public offering; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section entitled "Risk Factors" in Greenwich LifeSciences' Annual Report on Form 10-K for the year ended December 31, 2021 and other periodic reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Greenwich LifeSciences, Inc. undertakes no duty to update such information except as required under applicable law.


These press releases may also interest you

at 00:30
Al Yah Satellite Communications Company PJSC ("Yahsat") listed on the Abu Dhabi Securities Exchange ("ADX") under (SYMBOL: YAHSAT) (ISIN:...

30 jun 2022
Viettel Group and NVIDIA signed a Memorandum of Understanding (MoU) to establish a strategic partnership on using Artificial Intelligence (AI) to advance Viettel and Vietnam's technology research and solutions. Viettel is the first Vietnam company...

30 jun 2022
Server manufacturer Inventec (TPE: 2356) unveils  Mategress, the highest density storage JBOD with 42 SATA drives in a 2U enclosure to meet industry needs while improving efficiency with reduced costs. As demands for storage skyrockets, data centers...

30 jun 2022
The introduction of subscription services for STEM toys is expected to be a key trend of the Science, Technology, Engineering and Mathematics (STEM) Toys Market share growth. Many online retailers provide subscription services for STEM toys in...

30 jun 2022
Resecurity, a cybersecurity and intelligence company, today announced its award-winning cybersecurity threat intelligence and risk monitoring platform is now available on Microsoft's Azure Marketplace. Microsoft's Azure Marketplace is the most...

30 jun 2022
Resecurity, Inc., a U.S.-based cybersecurity and threat intelligence company, recently exhibited its solutions and shared its expertise at Eurosatory in Paris, France. Hosted June 13-17, 2022, Eurosatory is a leading international land and air...



News published on 23 may 2022 at 07:05 and distributed by: